Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older
Clinical trial NCT05650554 · COMPLETED
Trial details
- NCT number
- NCT05650554
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-12
- Primary completion
- 2024-04-02
- Enrollment
- 682
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.